Taipei, Taiwan, October 13, 2020 — Steminent Biotherapeutics Inc. (President & CEO; Dr. Ling-Mei Wang) and SCM Lifescience Co., Ltd. (KOSDAQ: 298060, hereinafter SCM Lifescience, CEO: BG Rhee) today announced they have signed an exclusive license agreement for clinical development and commercialization of Steminent’s allogeneic cell therapy candidate; Stemchymal® for the treatment of Polyglutamine Spinocerebellar Ataxia (PolyQ SCAs) in South Korea. [Read more…]
Cord Blood Registry (CBR®) by Generate Life Sciences Partners with NantKwest to Develop Covid-19 Treatment
CBR to Provide Umbilical Cord-Derived Cellular Material to NantKwest for additional COVID-19 Clinical Trials Utilizing MSC Therapy
Los Angeles, Calif., and El Segundo, Calif., August 10, 2020 – CBR® by Generate Life Sciences, the world’s largest private newborn stem cell bank, and NantKwest (Nasdaq: NK), a clinical-stage, natural killer cell-based immunotherapy company, announced a collaboration to develop a COVID-19 treatment leveraging newborn stem cells. CBR will provide research-donated umbilical cord tissue-derived mesenchymal stem cells (MSCs) to NantKwest for efficient and robust expansion utilizing their proprietary modular, closed bioreactor system from NantKwest affiliate ImmunityBio, Inc. [Read more…]
TreeFrog Therapeutics and Invetech Expand Partnership to Transition High-throughput Stem Cell Encapsulation Technology to GMP System for Commercial-scale Cell Therapy Manufacturing
-
TreeFrog Therapeutics and Invetech started their collaboration in 2019 to industrialize TreeFrog’s stem cell encapsulation technology to enable the mass production of hPSC-derived cell therapies in industrial bioreactors, with best-in-class cell quality and low production costs.
-
Invetech delivered a beta encapsulation system with a throughput of 1,000 stem cell capsules per second to TreeFrog Therapeutics in the second quarter of 2020.
-
The strategic partnership aims to develop a GMP-compliant encapsulation device by the end of 2022 to support TreeFrog Therapeutics’ in-house and partnered cell therapy programs.
FDA Grants Organicell Expanded Access to Treat COVID-19 Patients with Zofin(TM)
Miami, FL (September 29, 2020) – Organicell Regenerative Medicine, Inc. (OTCBB: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, announced that the U.S. Food and Drug Administration (FDA) granted expanded access for an intermediate size population allowing its proprietary therapeutic, Zofin for the treatment of COVID-19. [Read more…]
Ronawk Offering Free Samples of T-Blocks to Slash Stem Cell Expansion Costs & Labor Hours
OLATHE, Kansas — Ronawk, innovators in stem cell expansion technologies, has launched a trial program to provide its patented tissue-blocks (T-Blocks) to commercial cell producers and regenerative medicine partners. Their T-Blocks are a 3D matrix consumable product that enable the stem cell industry by providing means to increase stem cell production by 3,600 times vs. traditional expansion methods. [Read more…]
- « Previous Page
- 1
- …
- 85
- 86
- 87
- 88
- 89
- …
- 118
- Next Page »